NHS National Proprietary Pharmaceuticals - Low Molecular Weight Heparins and Fondaparinux Products
NHS England is seeking suppliers of low molecular weight heparins and fondaparinux products for a national framework. The contract runs for two years from March 2026, with options to extend for up to 24 months.
- Closed22 October 2025
- Value£176m
- BuyerNHS England
- CategoryHealth & medical
- RegionUK-wide
You'll want to look if you manufacture or distribute low molecular weight heparins or fondaparinux products and can supply NHS England at scale
Might not suit a small firm
- the contract itself is a large one
- it needs coverage across the whole UK
Possible incumbent
Dr Reddy's Laboratories, Novartis, Pfizer, Teva, and Wockhardt won related NHS national pharmaceutical frameworks in September 2025. Inferred from prior awards to this buyer, not confirmed.